The relationship between serum neopterin levels and disease activity in patients with spondyloarthropathy.

Authors

Ayza Kılıç, Rezan Koçak Ulucaköy, Zakir Osmanov, İdil Melis Çobanoğlu, Cemalettin Aybay, Feride Nur Göğüş

Published in

Biomarkers in medicine. Pages 1-8. Jun 21, 2026. Epub Jun 21, 2026.

Abstract

Biomarkers that accurately reflect disease activity and inflammatory burden are needed, particularly in the early stages of spondyloarthropathy (SpA). This study aimed to evaluate the association between serum neopterin levels and disease activity indices in patients with SpA.
This cross-sectional study included 84 participants based on a priori sample size estimation: 21 patients with axial SpA (axSpA), 21 with peripheral SpA (pSpA), 21 with active rheumatoid arthritis (RA) and 21 healthy controls (HC). Disease activity in SpA was assessed using the Axial Spondyloarthritis Disease Activity Score (ASDAS) and the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). A disease activity was assessed using the Disease Activity Score in 28 Joints (DAS28). Serum neopterin levels were measured by Enzyme-Linked Immunosorbent Assay.
Serum neopterin levels differed significantly among the groups (post-hoc, p = 0.007), with higher levels observed in patients with active RA than in those with axSpA, and no significant associations were found between neopterin levels and disease activity indices in either axial or peripheral SpA.
In the present study cohort, no significant association was observed between serum neopterin levels and disease activity in patients with axial or peripheral SpA.

PMID:
42324724
Bibliographic data and abstract were imported from PubMed on 22 Jun 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.